Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine plus riluzole for appetite loss in amyotrophic lateral sclerosis
2007-003775-39Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in amyotrophic lateral sclerosis (ALS) comparing Olanzapine 10 mg + riluzole 100 mg with Placebo + riluzole 100 mg (2 arms). Started Sep 2008; status: terminated.
02
Drugs
olanzapine
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2007-003775-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003775-39.